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Abstract 
Infections due to carbapenem-resistant Gram-negative bacteria are burdened by high 
mortality and represent an urgent threat to address. Clinicians are currently at a dawn of a 
new era in which antibiotic resistance in Gram-negative bacilli is being dealt with by the 
availability of the first new antibiotics in this field for many years. Although new antibiotics 
have shown promising results in clinical trials, there is still uncertainty over whether their use 
will improve clinical outcomes in real world practice. Some observational studies have 
reported a survival benefit in carbapenem-resistant Enterobacteriaceae bloodstream infections 
using combination therapy, often including “old” antibiotics such as colistin, 
aminoglycosides, tigecycline, and carbapenems. These regimens, however, are linked to 
increased risk of antimicrobial resistance, and their efficacy has yet to be compared to new 
antimicrobial options. While awaiting more definitive evidence, antibiotic stewards need 
clear direction on how to optimize the use of old and novel antibiotic options. Furthermore, 
carbapenem-sparing regimens should be carefully considered as a potential tool to reduce 
selective antimicrobial pressure. 
 
Keywords: Carbapenem-resistant Gram-negative bacteria, antimicrobial stewardship, new 
antibiotics, combination regimens, carbapenem-sparing  
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1. Introduction  
Carbapenem-resistant Gram-negative bacteria (CR GNB) are regarded by the Centers for 
Disease Control and Prevention (CDC) as posing an urgent threat to global health [1, 2]. The 
increase in infections caused by carbapenem-resistant Enterobacteriaceae (CRE) is 
particularly challenging due to the lack of consolidated first line treatment options. To treat 
severe infections caused by CRE, clinicians often rely on therapeutic regimens characterized 
by increased toxicity or suboptimal pharmacokinetics. In this scenario, the need for 
antimicrobial stewardship (AMS) programs is a critical matter. The cornerstone of AMS is 
optimization of appropriate antibiotic use in order to improve patient outcomes and to contain 
the emergence of further resistance [3,4]. Recently, two novel β-lactam-β-lactamase inhibitor 
combinations, ceftazidime-avibactam and meropenem-vaborbactam, received Food and Drug 
Administration (FDA) approval and became available to fight CRE infections. While this 
represents a unique opportunity, it also poses several challenges in AMS. Current data on the 
use of “old” antibiotics against CRE suggest that combination regimens (often including a 
carbapenem, colistin, an aminoglycoside, or tigecycline) provide some clinical advantage in 
selected patient populations [5-8] This, however, remains particularly problematic for 
antibiotic stewards when clinicians intend to use these regimens as empiric therapy. Given the 
likelihood that carbapenem use promotes carbapenem resistance, clear direction should be 
provided about when alternatives to carbapenems can be used. Data on the potential use of 
“carbapenem-sparing” regimens, however, remain conflicting [9,10].  
Here we outline these, and other, conundrums faced by clinicians in the current era of CR 
GNB and the arrival of new antibiotics. We have reviewed current and novel therapeutic 
options and provided proposals for the use of new antibiotics against CRE as well as 
multidrug-resistant (MDR) Pseudomonas aeruginosa and Acinetobacter baumannii. 
2. Challenges and benefits of the use of new antibiotics in AMS programs 
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The pipeline of new antibiotics active against MDR GNB is being rejuvenated by several new 
entities. These antibiotics fall into three main categories - “old” β-lactam antibiotics 
combined with “new” β-lactamase inhibitors (BLBLIs), “new” cephalosporins, and non-β 
lactam antibiotics. The approval or development status of some of these new antibiotics is 
summarized in Table 1. New β-lactamase inhibitors such as avibactam, relebactam and 
vaborbactam can inhibit the activity of Klebsiella pneumoniae carbapenemase (KPC), which 
is the most commonly encountered carbapenemase in both North America and Europe, as 
well as extended-spectrum β-lactamases and AmpC β-lactamases [11]. Novel cephalosporins 
include ceftolozane, used in combination with tazobactam for the treatment of MDR P. 
aeruginosa infections, and cefiderocol (S-649266), a novel siderophore cephalosporin stable 
against relevant carbapenemases including metallo-β-lactamases (MBLs), KPC 
carbapenemases, and OXA-48-group carbapenemases [12]. Other non-β lactam antibiotics, 
such as plazomicin and eravacycline, are not targeted by β-lactamases and also represent 
potential options for the treatment of CR GNB infections [13,14].  
Given the widespread nature of carbapenem resistance, these antibiotics have the potential to 
be widely used in the future. Some unanswered questions, however, remain on how 
to position them in hospital formularies and AMS programs. Firstly, although new antibiotics 
have a high degree of in vitro activity against CR GNB, some of them still need to 
demonstrate clinical efficacy in the setting of serious CR GNB infections. Trials aimed at 
determining the comparative efficacy of new compounds versus best available therapy (BAT) 
for the treatment of CR GNB are ongoing (Table 2). The development of large-scale 
randomized controlled trials (RCTs), however, is often not feasible in a reasonable time frame 
due to the limited number of patients with highly resistant serious infections who are suitable 
for enrollment in such trials. In 2017, the FDA evaluated the challenges in developing clinical 
programs for antibacterial drugs targeting single bacterial species [15], approving the Limited 
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Population Antibacterial Drug (LPAD) pathway. The newly granted LPAD pathway aims to 
provide a feasible mechanism to gain regulatory approval from smaller clinical studies for 
specific populations and areas of urgent unmet medical needs [16]. Secondly, until conclusive 
data on the superiority of new compounds versus traditional therapies become available, 
AMS programs need to weigh the trade-off between advantages and disadvantages pertaining 
to the different therapeutic options. Combinations of “old antibiotics” including meropenem, 
colistin and/or aminoglycosides have been associated to renal toxicity and may increase the 
selection pressure for CRE [17-19]. Conversely, ceftazidime-avibactam has shown good 
tolerability in clinical trials and represents a potential carbapenem-sparing option in the 
treatment of CRE. The cost of ceftazidime-avibactam, however, is significantly higher 
compared to colistin or aminoglycosides and exceeds more than 6 times the cost of 
meropenem. Finally, emergence of antimicrobial resistance and activity against different 
carbapenemases should also be considered to optimize AMS programs. Most new BLBLIs, 
including ceftazidime-avibactam and meropenem-vaborbactam, lack activity against MBLs, 
including New Delhi (NDM) and Verona integrin-encoded (VIM) that circulate in certain 
geographical areas (e.g. India, West Europe) [20,21]. For these reasons, antimicrobial 
susceptibility testing should always be available so that clinicians can make informed 
decisions regarding continuation of empiric therapy and antibiotic de-escalation [22]. The 
detection of specific resistance genes (KPC, NDM, VIM, and OXA-48 type) can also be 
performed using rapid and highly sensitive molecular tests that have been successfully 
employed in regional surveillance networks [23,24]. Diagnostic tests designed to screen CRE 
for specific carbapenemase enzymes from clinical specimens represent promising tools when 
used in conjunction with AMS interventions. Previous studies showed that molecular tests 
could rapidly detect GNB infections, direct appropriate choice for early antibiotic therapy, 
and improve patient outcomes [25,26].  
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2.1. Novel antibiotics for the treatment of CRE 
Ceftazidime-avibactam was the first new antibiotic to come to the market for the treatment of 
CRE infections [27]. Ceftazidime-avibactam has in vitro activity against MDR P. aeruginosa, 
KPC-producing K. pneumoniae (KPC-Kp), and some class D β-lactamases, including OXA-
48 that are becoming endemic in certain areas of Europe (e.g. Belgium, France, and Spain) 
[28-30].  
An association between KPC subtypes and ceftazidime-avibactam MICs has been reported. 
Specifically, higher median ceftazidime-avibactam MICs were detected against KPC-3 than 
KPC-2 variants due to the increased hydrolytic activity of KPC-3 against ceftazidime [31,32]. 
Development of ceftazidime-avibactam resistance among KPC-3-producing strains has also 
been documented [33-37]. Promising results were reported from observational studies 
comparing ceftazidime-avibactam with other therapies in the treatment of CRE infections. 
Shields et al. showed higher rates of clinical success among patients receiving ceftazidime-
avibactam than among those who received a carbapenem plus aminoglycoside (p=0.04), or 
colistin (p=0.009), or other regimens (p=0.004) [19]. The efficacy of ceftazidime-avibactam 
versus colistin was also assessed in a study including 137 patients from the CRACKLE 
(Consortium on Resistance Against Carbapenems in Klebsiella and other Enterobacteriaceae) 
cohort [38]. Compared to colistin, treatment with ceftazidime-avibactam showed higher 
probability of better outcomes (64%, 95% CI, 57-71%) and lower 30-day adjusted all-cause 
hospital mortality (9% vs. 32% respectively, p=0.001). Unfortunately, the emergence of 
resistance to ceftazidime-avibactam shown in pre-clinical studies has been confirmed by real-
world evidence [39]. Shields et al. reported emergence of ceftazidime-avibactam resistance in 
3 patients with ST258 KPC-Kp infection after 10, 15 and 19 days of therapy, showing MIC 
ranges increasing from 2/4 - 4/4 to 32/4 - 256/4 mg/L before and after treatment, respectively 
[33]. Whole genome sequencing (WGS) identified mutations in plasmid-borne blaKPC-3 in all 
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three patients [34,35]. Since ST258 KPC-3 strains predominate in US hospitals and have 
spread worldwide, the emergence of these resistant variants is concerning [36,40]. 
Interestingly, the mutation was able to restore meropenem susceptibility in some isolates. A 
potential restoration of meropenem susceptibility with KPC-3 variants conferring 
ceftazidime-avibactam resistance, however, remains an unpredictable event and has unclear 
implications in clinical practice [37]. Both et al. analyzed the emergence of resistance during 
treatment with ceftazidime-avibactam in an OXA-48-producing K. pneumoniae strain, which 
was associated with a mutation in CTX-M-14. Furthermore, WGS identified that additional 
CTX-M-independent mechanisms can contribute to resistance, suggesting that isolates with 
complex resistance mechanisms could impair the efficacy of ceftazidime-avibactam, 
especially when used as monotherapy [35]. For these reasons, the use of ceftazidime-
avibactam in combination with other antibiotics (e.g. aminoglycosides, polymixin B/colistin, 
tigecycline, or carbapenems) has been proposed [33,41]. There is currently not enough data, 
however, to universally support ceftazidime-avibactam use in combination versus 
monotherapy [42,43].  
Meropenem-vaborbactam has demonstrated excellent in vitro activity against KPC-producing 
Enterobacteriaceae, showing 99% of isolates to be susceptible with MIC50 and MIC90 values 
of 0.06/8 and 1/8 mg/L, respectively [44]. Against KPC producers, MICs were lower for 
meropenem-vaborbactam compared to ceftazidime-avibactam (MIC50 and MIC90 of 1/4 and 
4/4 mg/L, respectively) [45]. Furthermore, no differences in meropenem-vaborbactam MICs 
were shown between two engineered KPC-3 and KPC-2-producing K. pneumoniae derivative 
strains characterized by augmented efflux or multiple permeability defects (e.g. expression of 
major efflux pump AcrAB-TolC and defective porins OmpK35 and OmpK36) [45]. 
Meropenem-vaborbactam has no improvement in activity over meropenem alone against 
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strains producing OXA-48-group carbapenemases, MBLs, and lactose-non-fermenting CR 
GNB [45].   
A Phase 3 open-label study encompassing 72 patients with various CRE infections, including 
bloodstream infections (BSI), complicated urinary tract infections (cUTI), hospital-acquired 
or ventilator-associated pneumonia (HAP/VAP), and complicated intra-abdominal infections 
(cIAI), compared the efficacy of meropenem-vaborbactam (2g/2g q8h in a 3h infusion) versus 
BAT (ceftazidime-avibactam monotherapy or treatment with a carbapenem, an 
aminoglycoside, polymyxin B/colistin, or tigecycline monotherapy or combination 
treatment). While this was a non-inferential, descriptive trial, meropenem-vaborbactam was 
associated with significantly increased clinical cure rate and lower all-cause mortality rate at 
day 28 compared with BAT (68% vs. 27%, p=0.008 and 5% vs. 33%, p=0.03 respectively) 
[46]. Fortunately, current data show low propensity of meropenem-vaborbactam for 
resistance selection and infrequent cross-resistance between meropenem-vaborbactam and 
ceftazidime-avibactam [44,47,48]. Of 991 KPC isolates tested, 0.4% and 1.8% were resistant 
to meropenem-vaborbactam and ceftazidime-avibactam, respectively [44]. 
Plazomicin is a new generation aminoglycoside with increased in vitro activity against KPC-
producing bacteria compared to older aminoglycosides due to increased stability against 
various aminoglycoside-modifying enzymes [49,50]. Similarly to gentamicin and amikacin, 
however, the activity of plazomicin is limited against NDM-group MBLs due to production 
of 16S ribosomal RNA methyltransferases [51]. In the CARE study, which included patients 
with BSI or HAP/VAP due to CRE, 17 patients were treated with plazomicin (15 mg/kg once 
daily) while 20 received colistin in combination with meropenem or tigecycline. All-cause 
mortality was nominally lower for plazomicin compared to colistin (24% vs. 50%, difference 
26.5%, range -0.7 to 51.2), while serum creatinine increase was higher in the colistin arm 
(38% vs. 8%, respectively) [52]. Based on these efficacy and safety data, a recent FDA 
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briefing document confirmed plazomicin indication for the treatment of cUTI but did not 
recognize substantial evidence for recommending its use in BSI [53,54]. 
Eravacycline is a novel fluorocycline antibiotic that is structurally similar to tigecycline [55]. 
Eravacycline is not affected by most mechanisms causing tetracycline resistance and is active 
against ESBL-, KPC- and OXA-producing Enterobacteriaceae, MDR A. baumannii and 
Stenotrophomonas maltophilia [56]. As a tetracycline, eravacycline is not active against P. 
aeruginosa. The FDA recently approved the intravenous formulation of eravacycline for the 
treatment of cIAI, based on the IGNITE 1 and 4 trials showing non-inferiority of eravacycline 
compared with ertapenem and meropenem, respectively [57,58]. For cUTI, however, 
eravacycline was inferior to levofloxacin (IGNITE 2 and 3 trials), probably due to the drug’s 
suboptimal urinary pharmacokinetics [59,60]. The oral formulation of eravacycline has also 
shown limited bioavailability and reduced efficacy in cUTI compared to oral levofloxacin 
[59,60]. As such, no novel oral options are currently available to allow sequential step-down 
therapy against CRE-related infections. 
3. Old antibiotics used for the treatment of CRE 
Various “old” antibiotics, such as aminoglycosides, tigecycline, fosfomycin, and polymyxins 
often retain activity against CRE and are employed in clinical practice, usually as part of 
combination regimens.  
CRE are frequently susceptible to aminoglycosides such as gentamicin and amikacin, with the 
exception of 16S rRNA methyltransferase-producing isolates that circulate among NDM and, 
occasionally, KPC-producing strains [61]. Aminoglycosides are commonly used as part of 
combination treatment in the management of infections caused by CRE. Clancy et al. 
demonstrated in vitro bactericidal activity of gentamicin against KPC-2-producing K. 
pneumoniae carrying a mutant ompK35 porin gene and higher efficacy of doripenem-
gentamicin compared with doripenem-colistin combination (79% vs. 29% respectively, 
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p=0.02) [62]. A retrospective study examining 50 cases of sepsis caused by an outbreak of 
CR K. pneumoniae producing KPC-3, SHV-11 and TEM-1 showed that targeted use of 
gentamicin was independently associated with reduced mortality (21% versus 62%, p = 0.02) 
[63]. Decreased susceptibility to aminoglycosides, however, is emerging. MICs close to 
gentamicin and amikacin breakpoints have been associated to inadequate pharmacokinetic-
pharmacodynamic (PK/PD) targets, especially among critically ill patients [64]. Furthermore, 
aminoglycosides breakpoints have been recently reassessed by USCAST (National 
Antimicrobial Susceptibility Testing Committee for the United States) using applications of 
PK/PD models and MIC distribution statistics, resulting in lower susceptibility breakpoints 
compared to those by the CLSI (Clinical and Laboratory Standards Institute) and EUCAST 
(European Committee on Antimicrobial Susceptibility Testing) [65]. The impact of the newly 
updated breakpoints on aminoglycoside resistance rates has been recently analyzed at a 
tertiary hospital, showing a marked decrease in susceptibility of CRE to amikacin and 
gentamicin (86% vs. 55% and 31% vs. 21% using USCAST or CLSI guidelines, respectively) 
[66]. 
Tigecycline, the first glycylcycline to be approved for clinical use, usually retains in vitro 
activity against CRE [6,8,67-69]. Susceptibility rates of 95% and 89% to tigecycline were 
reported in CRE isolates from Africa, Middle East, and Europe, respectively, showing MIC90 
of 2 mg/dl [67,68]. Tigecycline is usually used in association with colistin, aminoglycosides, 
or meropenem against severe KPC-Kp infections [68,69]. Tigecycline does not exhibit 
efficient bactericidal activity against most of KPC-producing strains in time-kill studies when 
used as single agent [70]. In a multicenter, observational study including 125 KPC-Kp BSI 
showing overall tigecycline susceptibility of 91%, significant reduction in 30-day mortality 
was reported when combination therapy with tigecycline, colistin and meropenem was used 
instead of monotherapy with colistin or tigecycline (p=0.02) [6]. In severe infections, some 
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studies suggested that high-dose tigecycline (200 mg initially, then 100 mg twice daily) might 
improve clinical outcomes [71]. In a phase II randomized trial of HAP, a trend towards 
increased cure rates was shown for patients treated with high-dose compared with standard 
dose tigecycline or with imipenem–cilastatin (85% vs. 70% and 75%, respectively) [72]. 
High-dose tigecycline was also associated with higher clinical cure rates and microbiological 
eradication compared with the standard dose in an observational study including 100 
critically ill patients (p=0.08 and p=0.10, respectively) [73]. Experimental models of 
pneumonia due to NDM-1-producing K. pneumoniae and E. coli strain demonstrated that 
high-dose tigecycline was more effective than colistin, which did not reach sufficient drug 
levels in the lung tissue [74]. Well-controlled studies, however, are still needed to evaluate 
the efficacy and safety profiles of high-dose tigecycline, especially in HAP/VAP.  
The polymyxins (including polymixin E/colistin and polymixin B) are an old class of 
antibiotics displaying in vitro activity against most MDR GNB. Both polymyxins have been 
extensively used in infections due to CRE, although more data and clinical experience exist 
for colistin [6,8]. Main limitations associated with colistin use include potential 
nephrotoxicity, unpredictable PK due to use of prodrug, and dosing regimens that are not well 
established [75-78]. Monotherapy with polymyxins is associated with emergence of 
resistance in vitro, suggesting that this class should be administered in combination with other 
agents [79]. Some clinical studies also demonstrated increased efficacy of colistin when used 
in combination with other drugs [80,81]. In the INCREMENT cohort, colistin monotherapy 
was associated with increased mortality compared to combinations of tigecycline, colistin, or 
carbapenems [82]. Conversely, among 406 patients with severe infections caused by CR 
GNB enrolled in an international randomized trial, colistin combined with meropenem 
showed similar clinical failure rates compared with colistin monotherapy (73% vs. 79% 
respectively, risk difference -5.7%, 95% CI, -13.9-2.4). This trial, however, included mainly 
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A. baumannii isolates and was underpowered to compare treatment outcomes for other GNB, 
including CRE [83]. A similar RCT is currently ongoing and should provide data on the 
efficacy of colistin monotherapy for infections caused by CRE (Table 2). 
Colistin use has been limited by emergence of resistance among KPC-Kp, with reported rates 
up to 40% especially in areas burdened by high CR prevalence [84,85]. The recent discovery 
of plasmid-mediated colistin resistance has also important implications for the spread of these 
highly resistant strains [86]. 
Despite decades of use in the treatment of UTI, fosfomycin still displays in vitro activity 
against the majority of MDR Enterobacteriaceae, including MBL producers [87,88]. A small, 
prospective, single-arm study assessed intravenous fosfomycin safety and effectiveness as 
part of combination regimens with colistin or gentamicin in 11 critically ill patients with 
severe CR-Kp infections. Fosfomycin was well tolerated and all-cause in-hospital mortality 
was 18% [89]. In a multicenter prospective case series, intravenous fosfomycin was 
administered in combination with colistin or tigecycline to 68 ICU patients with BSI or VAP 
caused by CR K. pneumoniae (60%) or P. aeruginosa (40%). Favorable clinical outcome and 
bacterial eradication were observed in 54% and 56% of patients, respectively, while 
fosfomycin resistance developed in three cases [90].  
Oral antimicrobial options for the treatment of resistant infections caused by GNB are 
lacking. Oral fosfomycin is currently not indicated for systemic MDR GNB infections and in 
most countries is only approved as a 3 g single dose for treatment of uncomplicated cystitis. 
Due to the poor bioavailability shown by the oral formulation, currently recommended 
fosfomycin dosing regimen appears insufficient to achieve efficacious serum and tissue 
concentration and to suppress emergence of resistance [91].  Although population PK models 
estimated that 6 to 12 g per day may be required to obtain optimal oral fosfomycin exposure, 
more data on surrogate PD indices are needed to investigate potential safety issues associated 
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with high-dose fosfomycin [91].  
Minocycline could also represent an option for sequential therapy in the treatment of MDR 
GNB. To date, however, minocycline activity on CRE has only been documented by in vitro 
studies [92].  
3.1. Combination versus monotherapy for CRE treatment 
There are currently no RCTs comparing combination therapy with monotherapy for CRE 
infections. Data reporting the superiority of combination treatment (most often including 
meropenem, colistin, gentamicin, or tigecycline) versus monotherapy have been limited due 
to the observational nature of the studies and included mainly KPC-Kp isolates [5,6,8,93]. 
Qureshi et al. showed higher 28-day survival for combination therapies including a 
carbapenem, tigecycline, or a fluoroquinolone versus monotherapy (57.8% vs. 13.3% 
respectively, p=0.01) in 41 patients with KPC-Kp BSI [93]. A study encompassing 661 
patients with KPC-Kp infections documented lower 14-day mortality for combination therapy 
with at least two in vitro active drugs (e.g. meropenem plus colistin, gentamicin, or 
tigecycline) compared with monotherapy (30% vs. 38% respectively, p=0.03) [8]. Higher 
survival was associated with meropenem MICs ≤8 mg/L compared with MICs >8 mg/L (24% 
vs. 35% respectively, p=0.005). Daikos et al. compared the outcomes of 205 patients with 
BSI caused by KPC-, VIM-, and KPC/VIM-producing K. pneumoniae treated with 
combination therapy (including tigecycline, an aminoglycoside, or colistin in 67% of cases) 
with those receiving monotherapy with meropenem, colistin, tigecycline, or an 
aminoglycoside. Higher 28-day mortality was reported for monotherapy compared with 
combination treatment (44% vs. 27% respectively, p=0.018), while the lowest mortality rate 
(19%) were associated with carbapenem-based triple combinations (e.g. meropenem plus 
tigecycline plus colistin or an aminoglycoside) [5]. A correlation between carbapenem MICs 
and mortality has also been confirmed by other studies. High-dose meropenem (2g q8h by 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
  14 
extended infusion) was more likely to be effective against CRE if MICs were <8 mg/L [8]. 
Positive clinical outcomes, however, were reported also for higher MICs [94]. A recent study 
in critically ill patients highlighted that meropenem doses of 8 and 12 grams/day by 
continuous infusion may be necessary to reach PK/PD targets for MICs of 32 and 64 mg/L, 
respectively [95].  
Some studies do not support the superiority of combination therapy over monotherapy for the 
treatment of CRE infections. Gomez-Simmonds et al. analyzed 141 patients with BSI due to 
CR-Kp (MIC90 of >16 mg/L) showing comparable 30-day mortality in those receiving 
monotherapy versus combination therapy (26% vs. 38%, respectively, p=0.1). Forty-eight % 
received monotherapy (75% with either polymyxin B or tigecycline) while 52% were treated 
with combination therapy including -lactams, tigecycline, aminoglycosides, and polymixin 
B. [96]. In a recent multicenter prospective study encompassing 437 patients with CRE BSI, 
mainly caused by KPC-Kp, the overall mortality rates were comparable between patients 
receiving combination of colistin plus tigecycline, an aminoglycoside plus tigecycline, or 
colistin plus a carbapenem versus monotherapy with colistin, a carbapenem or an 
aminoglycoside, or tigecycline (35% vs. 41% respectively, p=0.28). A lower mortality rate, 
however, was recorded among patients receiving combination therapy in the high-mortality-
score stratum compare with the low-mortality-score stratum (48% vs. 62% respectively, 
p=0.02) [82].  
Systematic reviews aimed at comparing the efficacy of combination therapy vs. monotherapy 
found major limitations in the studies included for analysis (e.g. heterogeneity of infection 
sites, pathogen types, and different susceptibility breakpoints) and could not provide 
definitive data favoring one strategy over the other [80,97,98].  
4. Carbapenem-sparing regimens  
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Carbapenems have long been regarded as the treatment of choice for infections due to ESBL-
producing bacteria. Some data, however, suggest that BLBLIs such as piperacillin-
tazobactam may be as effective as carbapenems against ESBL producers [9,99-102]. In the 
absence of other concomitant mechanisms of resistance, such as AmpC enzymes, amoxicillin-
clavulanic acid and piperacillin-tazobactam may be active against ESBL producers [103]. 
Although the use of carbapenem-sparing regimens appears to be a sensible option in the 
treatment of ESBL-producing strains in order to reduce further selection of carbapenem 
resistance, controversial data on the efficacy of BLBLIs, in particular piperacillin-tazobactam, 
recently emerged. Current evidence suggests that piperacillin-tazobactam activity is impaired 
when lower doses are used instead of higher doses (e.g. 4.5 g every 6 h, administered by 
extended infusion) or for infections with high inoculum, such as undrained abscesses or 
pneumonia [9,104-106]. A retrospective study of BSI due to ESBL producers, mostly K. 
pneumoniae, found higher mortality among patients treated with empiric piperacillin-
tazobactam compared with carbapenems [10]. Furthermore, the results of a non-inferiority 
RCT (MERINO trial) comparing piperacillin-tazobactam with meropenem in 378 patients 
with BSI due to ceftriaxone non-susceptible Escherichia coli and K. pneumoniae do not 
support the use of piperacillin-tazobactam as a carbapenem-sparing therapy in these 
infections [107]. Specifically, 12% of patients in the piperacillin-tazobactam arm and 4% in 
the meropenem arm met the primary outcome of mortality (risk difference 8.6%, p=0.90 for 
non-inferiority) [108]. Based on these data, carbapenem use should be preferred among 
patients with high-inoculum infections or septic shock due to ESBL producers, including 
those with BSI (Table 3). 
Among other molecules, aminoglycosides are also active against ESBL [109,110] and may be 
useful in cUTI and sepsis, although concerns regarding toxicity and limitation in PK/PD 
target attainment have been reported [49]. In areas with high ESBL prevalence, addition of an 
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aminoglycoside to piperacillin-tazobactam could be useful for empiric therapy (Table 3). 
Fosfomycin is also being studied as an alternative to carbapenems for UTI due to ESBL-
producing bacteria and for step-down therapy, however definitive data are still not available 
[111,112]. Another potential carbapenem-sparing option is tigecycline, but limited data are 
available for infections caused by ESBL-producing organisms.  
The use of new BLBLIs as carbapenem-sparing regimens also remains controversial. 
Although ceftazidime-avibactam and ceftolozane-tazobactam display excellent activity 
against ESBL producers, they should generally be reserved for the treatment of CR GNB 
infections [11], given the recent real-world data supporting the use of these agents as valid 
alternatives to carbapenem-based regimens for CR GNB infections [19,33,38,43,113-115] 
(Table 3). Another practical limitation in the use of these novel agents as carbapenem-sparing 
options for ESBL infections is their high cost compared to meropenem, which is the standard 
of care.  
5. Treatment strategies for MDR A. baumannii  
A. baumannii has acquired resistance genes to several antibiotics, including carbapenems. 
The efficacy of colistin in severe infections caused by CR A. baumanni has been 
demonstrated in retrospective studies [116,117], and its use has been proposed for empiric 
therapy in high-risk patients and in endemic areas [118]. Emergence of colistin resistance, 
however, currently represents a worrisome perspective not only for CRE but also for the 
management of MDR A. baumanni infections [119]. Several in vitro and experimental studies 
suggest a potential synergism between colistin and rifampin against XDR-A. baumanii, due to 
colistin’s ability to enhance rifampin penetration into bacterial cells by altering the membrane 
permeability [120,121]. However, a randomized trial comparing colistin monotherapy with 
colistin plus rifampin in 210 ICU patients showed similar 30-day mortality rates (43.3% vs. 
42.9%) despite increased microbiologic eradication among those receiving combination 
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therapy with rifampin compared with monotherapy (61% vs. 45%, p=0.034) [122]. The 
numerous drug-drug interactions caused by the inducing effect of rifampin on cytochrome 
P450 and the lack of evidence for clinical superiority represent significant limitations to 
rifampin use in clinical practice. In vitro synergism between fosfomycin and colistin has also 
been reported against A. baumannii [123]. Similar to rifampin, in a RCT including 94 patients 
with CR A. baumannii infections the combination of colistin plus fosfomycin did not 
demonstrate clinical superiority but showed increased microbiological eradication versus 
monotherapy (100% vs. 81%, respectively; p=0.01) [124]. Larger studies are needed to 
confirm these results. 
In a recently reported randomized trial, colistin-meropenem combination therapy did not 
result in better survival, clinical cure, or microbiological cure compared to colistin 
monotherapy in patients with infections due to CR GNB, including 77% of patients with A. 
baumannii infections [83]. A high patient mortality rate (44% at day 28) was reported even 
among patients with relatively low Charlson comorbidity index and SOFA score, highlighting 
the urgent need for new antibiotic options against CR A. baumanni. 
The β-lactamase inhibitor sulbactam is not affected by common carbapenemases in A. 
baumannii, such as OXA-23, and retains activity against CR A. baumanni. A small RCT 
including 28 patients treated with ampicillin-sulbactam versus colistin showed comparable 
efficacy (62% vs. 60%, respectively) in the treatment of VAP caused by MDR A. baumannii 
[125]. In a retrospective study including 98 patients with VAP due to CR A. baumannii, 
colistin was associated with a lower microbiological response rate compared to sulbactam 
(18% vs. 48%, respectively; p=0.03) although the clinical cure rates were similar in both 
groups. [126]. These data suggest that sulbactam-based regimens may be a valid alternative 
for infections caused by MDR A. baumannii (Figure 1). 
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Tigecycline often retains in vitro activity against A. baumannii. Tigecycline use, however, is 
not recommended in BSI and pneumonia, which represent the most frequent infections 
associated with A. baumannii, due to concerns over its unique pharmacokinetics. A recent 
meta-analysis assessing the efficacy of tigecycline showed that higher in-hospital mortality 
(OR=1.57, 95% CI 1.04-2.35; p=0.03) and lower microbial eradication (OR=0.20, 95% CI 
0.07-0.59; p=0.003) were associated with tigecycline therapy versus comparators in the 
treatment of MDR A. baumannii [127]. Despite multiple limitations were identified in the 
studies included in the meta-analysis (e.g. small sample size, high heterogeneity, and lack of 
RCTs), current data do not support the use of tigecycline in this indication. Further studies are 
needed to investigate a potential role of tigecycline in association with other active 
antimicrobials in the treatment of CR A. baumannii. 
Minocycline showed high susceptibility rates (79% compared with 99% of colistin) when 
tested against 5478 clinical isolates of A. baumannii [128]. Furthermore, minocycline 
administered 100-200 mg twice daily intravenously has shown bactericidal activity and 
enhanced effects if combined with colistin or other susceptible antimicrobials against resistant 
A. baumannii [129]. Intravenous minocycline has recently received FDA approval (Qualified 
Infectious Disease Product designation under the Generating Antibiotic Incentives Now act) 
for the treatment of hospitalized patients with MDR Acinetobacter spp. infections. Although 
no RCTs have been performed, clinical data support the efficacy of minocycline in the 
treatment of MDR Acinetobacter spp. [130]. A review including 126 patients and 141 isolates 
from 7 studies reported an overall clinical success rate of 78% (range 50% to 89%) [131]. The 
two largest studies, including 35 and 55 patients with respiratory infections and BSI, showed 
clinical improvement in 81% and 73% of patients, respectively [132,133]. Minocycline 
monotherapy was mainly used for respiratory tract infections showing clinical success rates 
between 82% and 100%.  
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6. Treatment strategies for MDR P. aeruginosa 
Development of P. aeruginosa resistance to β-lactams and fluoroquinolones has been 
documented worldwide [134,135]. The extensive use of carbapenems likely contributed to the 
increase of CR P. aeruginosa through different mechanisms, including production of MBL 
carbapenemases, AmpC β-lactamases, overproduction of efflux systems, and alterations in 
outer membrane porins [134,135]. Among carbapenems, ertapenem has shown little activity 
against Pseudomonas spp. and could be considered, when possible, as an option to reduce the 
selective pressure on Pseudomonas and to avoid the use of other carbapenems. Although few 
clinical studies have shown no association between ertapenem use and 
decreased Pseudomonas aeruginosa susceptibility, conflicting results on the selection for 
mutants with cross-resistance to other carbapenems have been reported [136]. 
Combination therapy for suspected infections caused by Pseudomonas spp. usually includes 
an antipseudomonal β-lactam (e.g. piperacillin-tazobactam, ceftazidime, cefepime) and a 
fluoroquinolone or an aminoglycoside. In areas with high prevalence of MDR Pseudomonas, 
however, alternatives to the classic antipseudomonal drugs may be necessary. 
Ceftolozane-tazobactam has shown activity against the majority of CR P. aeruginosa and 
stability against overexpression of Pseudomonas-derived cephalosporinases or efflux pumps, 
conserving activity against the majority of pan-β-lactam-resistant clinical strains [137]. 
Ceftolozane, however, is susceptible to hydrolysis by carbapenemase enzymes (e.g. MBL, 
KPC) and is not protected by tazobactam. Clinical efficacy of ceftozolane-tazobactam has 
been demonstrated in the treatment of cUTI and abdominal infections, although the number 
of patients infected with P. aeruginosa in the studies was limited [26,114,138].  
In several in vitro studies against P. aeruginosa, avibactam has been shown to reverse 
ceftazidime resistance, reducing ceftazidime MICs to values lower than the EUCAST and 
CLSI breakpoints [139,140]. A Phase 3 trial confirmed efficacy of ceftazidime-avibactam 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
  20 
comparable to BAT (represented by carbapenem monotherapy in >95% of cases) in 333 
patients with cUTI or cIAI caused by ceftazidime-resistant Enterobacteriaceae or P. 
aeruginosa. Clinical cure rates with ceftazidime-avibactam or BAT were both 91%. 
Nevertheless, only a small proportion (7%) of ceftazidime-resistant P. aeruginosa infections 
were included in the study, and more evidence is needed to support the use of ceftazidime-
avibactam as a potential alternative to carbapenems in these infections [141]. 
Colistin, usually in association with meropenem, has been employed to treat MDR P. 
aeruginosa [142-144]. The use of aminoglycosides also represents a valid alternative in 
combination therapy, although the high risk of renal toxicity limits its association with 
colistin in clinical practice [145].  
Fosfomycin use in the treatment of MDR P. aeruginosa has been reported by few 
retrospective studies as part of combination regimens including colistin, tigecycline, or a 
carbapenem [90,145,146], but further data are necessary to confirm its efficacy.  
As reported for Enterobacteriaceae, extended infusion of β-lactams appears as a promising 
option also for treatment of Pseudomonas severe infections [146-150]. Treatment 
recommendations for severe infections due to MDR Pseudomonas spp. are listed in Figure 1.  
7. Treatment recommendations for CRE infections and relevance to AMS programs 
7.1. General considerations for antibiotic selection 
Relevant AMS elements include preservation of activity of new therapeutic options and the 
reduction of unnecessary use of antimicrobials [4]. In areas where CR infections are 
commonly reported, antibiotic stewards need to optimize the use of old antibiotic options and 
wisely select the novel compounds available in order to achieve better outcomes while 
reducing antibiotic resistance. 
Key elements that guide treatment selection for CRE infections include drug availability, data 
from well-designed clinical studies, access to susceptibility testing, and local epidemiology. 
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According to these variables, many patients will require individualized antibiotic therapy 
regimens [150,151]. Furthermore, new BLBLIs are characterized by susceptibility that 
changes as a function of the type of specific carbapenemase present [11]. Due to known 
significant differences in the worldwide distribution of carbapenemase-producing 
Enterobactericeae, local epidemiology will likely influence the therapeutic roles of the new 
agents and the choice of an empiric treatment [20,21,28-30]. Antibiotic selection and dosing 
are also influenced by PK/PD parameters. Attaining adequate PK/PD targets is an essential 
goal in the treatment of MDR infections, especially among critically ill patients [152]. 
Standard dosing regimens, however, may not be sufficient to achieve exposures consistent 
with efficacy if the breakpoints are set too high, as shown by PK/PD target attainment 
analyses on old antibiotics such as carbapenems or aminoglycosides in pre-clinical infection 
models [51,153]. The presence of optimal - or suboptimal - breakpoints for old antibiotics 
should also be taken into consideration when selecting the most effective antimicrobial 
regimen against MDR GNB.  
Other aspects that need to be considered in the decision-making process for antimicrobial 
therapy of patients with CRE infections include the source of infection (e.g. VAP/HAP, cUTI, 
cIAI, etc.) and patient characteristics such as comorbidities, renal function, and infection 
severity. According to a validated mortality score (INCREMENT CPE score), combination 
therapy rather than monotherapy may be beneficial for high-risk patients characterized by 
certain clinical conditions (e.g. presentation with severe sepsis or shock, ≥6 points on the Pitt 
bacteremia score, ≥2 points on the Charlson comorbidity index, and source of BSI other than 
the urinary or biliary tract) [82]. In patients with low mortality risk, monotherapy may be 
sufficient. Other studies found that combination therapy was protective in patients with septic 
shock and in BSI from non-urinary sources [5,8]. Lower mortality has been associated with 
combination therapy compared to monotherapy among patients with septic shock caused by 
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colistin-resistant, highly carbapenem-resistant KPC-Kp BSI [7].  
Finally, since prevention of the unnecessary use of antimicrobials is particularly relevant to 
AMS programs, careful evaluation of the clinical significance of a CRE isolate should be 
performed to confirm the presence of colonization versus infection [154].  
7.2 Therapy of CRE 
7.2.1 New antimicrobials 
Preliminary data demonstrated that patients experienced improved outcomes (e.g. decreased 
mortality, higher clinical success, and lower toxicity) with new BLBLI combinations over 
traditional CRE therapies for KPC-Kp infections [19,38,46]. For these reasons, the use of 
either ceftazidime-avibactam or meropenem-vaborbactam is currently considered as the 
preferred option for the treatment of infections caused by CRE (Figure 1). There are not 
enough data to directly compare the efficacy of ceftazidime-avibactam versus meropenem-
vaborbactam and indicate a preferred agent. It is likely, however, that both drugs will be 
needed for the management of these infections. 
Due to avibactam’s inhibitory capability against OXA-48 and ceftazidime’s stability to 
hydrolysis by this enzyme, ceftazidime-avibactam represents the preferred agent for the 
treatment of OXA-48 producers over meropenem-vaborbactam. Furthermore, ceftazidime-
avibactam represents a carbapenem-sparing option for AMS programs and has activity 
against CR P. aeruginosa. Against MBLs, ceftazidime-avibactam has the potential to be 
associated with aztreonam, which is not hydrolyzed by these enzymes, while avibactam 
maintains inhibitory activity against non-MBL -lactamases [155]. Clinical data associated 
with the use of this combination, however, are scarce [156]. The aztreonam-avibactam 
combination is currently under clinical development and represents a promising option for the 
management of CRE infections, including those caused by MBL producers. 
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In areas with low prevalence of OXA-48-group carbapenemases, such as the US, 
meropenem-vaborbactam could be preferred over ceftazidime-avibactam due to its higher 
potency against KPC producers and the potentially lower propensity for development of 
resistance [44,45]. More data are needed to determine if meropenem-vaborbactam can act as a 
rescue therapy to ceftazidime-avibactam resistance, for example due to the potential 
restoration of carbapenem susceptibility shown by KPC-3 mutants [33,37], and to assess 
whether its higher potency against KPC enzymes translates into better outcomes. Of note, it 
will be important to determine if ceftazidime-avibactam or meropenem-vaborbactam can 
select for resistance mechanisms that may compromise the use of both novel therapies. This is 
particularly relevant to AMS programs in order to select a preferred agent for clinical use. 
Due to the presence of complex and concomitant mechanisms of resistance and the possibility 
of selecting resistance during treatment of CRE infections, it is highly recommended to 
routinely test ceftazidime-avibactam and meropenem-vaborbactam susceptibilities and to 
repeat testing in patients with persistently positive cultures [28]. 
It remains unclear whether ceftazidime-avibactam should be used as monotherapy or 
combined with other agents. Various studies have reported its use in combination with an 
“old” agent (most frequently aminoglycosides, but also polymyxins, tigecycline, and 
carbapenems) [32,40,41]. This approach in our opinion appears reasonable, especially in 
severe infections and to potentially prevent resistance development [33]. Although in vitro 
studies have investigated the synergy of ceftazidime-avibactam with other compounds, there 
are still not enough data to recommend the optimal accompanying drug and clinical scenarios 
under which such combinations should be implemented [157]. In low risk patients 
(INCREMENT score < 8), ceftazidime-avibactam could potentially be used as monotherapy 
[82]. 
7.2.2 Old antimicrobials 
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Carbapenems 
When ceftazidime-avibactam or meropenem-vaborbactam cannot be used for the treatment of 
CRE infections, or meropenem displays MICs ≤ 8 mg/L, the use of a carbapenem in 
combination with another active agent is recommended according to the source of infection 
and the pathogen’s susceptibility profile [5,6]. As previously discussed, in confirmed CRE 
infections, a PK/PD optimized, MIC-driven approach is advisable for meropenem use, 
especially in critically ill patients [94,95]. Carbapenem use may also be beneficial when the 
combination of other in vitro active drugs is suboptimal according to the source of infection 
(e.g. use of tigecycline for cUTI and tigecycline or an aminoglycoside for VAP, due to poor 
drug concentrations at the sites) or because of increased nephrotoxicity (e.g. colistin and 
aminoglycosides). Limitations in the use of carbapenems are represented by their 
controversial efficacy against non-KPC carbapenemase producers and non-carbapenemase-
producing CRE [158,159]. Furthermore, AMS programs should consider the negative 
ecological effects of an increased use of carbapenems to treat CRE, which may lead to further 
selection of resistance.  
A double carbapenem regimen, including ertapenem plus doripenem or meropenem, has been 
used for the treatment of pandrug-resistant CRE with some evidence of efficacy in small 
observational studies [160]. The rationale for the combination is the high affinity of 
ertapenem for the KP  enzymes, allowing the binding of another carbapenem to the 
penicillin binding protein [160]. Although some reports have documented successful 
outcomes with this approach, its efficacy may be simply attributable to the overall high dose 
of carbapenem administered, and the strategy remains limited against organisms with 
OmpK36 porin mutations, known to increase carbapenem MICs [160-162]. Therefore, a 
double carbapenem combination should be considered only when there are no other available 
options.  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
  25 
Polymyxins 
Polymyxins are still frequently used as backbone for the treatment of CRE, despite concerns 
raised over dosing uncertainties and toxicity, especially among renally compromised and 
elderly patients [75]. Current data suggest that colistin-containing combination therapy is 
more beneficial than colistin monotherapy for high-risk patients with CRE infections [79-82]. 
A loading dose of 9 MU followed by 9 MU q24h divided in two or three doses is currently 
recommended, with dose adjustments performed according to renal function [75,163]. Due to 
its potential toxicity and suboptimal PK, colistin should be used when other options are 
limited (e.g. meropenem MIC >8 mg/L and susceptibility only to colistin and another agent) 
and preferentially in combination (Table 1). Co-administration of colistin and 
aminoglycosides has high nephrotoxic potential and should be avoided whenever possible. 
Aminoglycosides 
Aminoglycosides show variable - but often significant - in vitro susceptibility against CRE 
[8,38]. Although studies comparing the outcomes for patients treated with and without 
aminoglycosides are scarce, gentamicin (5 - 7 mg q24h) or amikacin (15 to 20 mg q24h) have 
been frequently used, especially in combination, in the management of infections caused by 
CRE [5,6,8,93]. Specifically, the use of aminoglycosides was associated with better outcomes 
in cUTI [38,164]. As a general rule, dose adjustments based on therapeutic drug monitoring 
are recommended during therapy with aminoglycosides [165]. The optimal dose of these 
drugs in severe infections, however, is still not well established. Some studies employing high 
doses of amikacin (>25 mg/kg/day) have been linked with higher probability of reaching 
PK/PD targets especially in critically ill patients, although further data are needed to 
recommend the use of these doses in CRE infections [166,167]. 
Tigecycline  
Tigecycline may be useful as part of treatment regimens based on susceptibility tests and 
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source of infection [5,6,8,93]. Tigecycline concentrations in urine are low, and this drug has 
been evaluated in this indication only in few reports [168]. Tigecycline has been associated 
with a lower rate of KPC-Kp clearance in patients with bacteriuria or cUTI compared with 
aminoglycosides [164,165]. Tigecycline use in cUTI appears therefore suboptimal and should 
not be considered as first line treatment. More generally speaking, we do not recommend the 
use of tigecycline as monotherapy for CRE [6]. Increased tigecycline doses are suggested for 
severe infections, such as HAP, and may be considered for other infections with suboptimal 
drug concentrations, such as BSI and cUTI [70-73]. More clinical data, however, are required 
to support the use of high-dose tigecycline regimens for the treatment of HAP and other types 
of infections. 
Fosfomycin 
Because of the paucity of data associated with the use of fosfomycin in CRE infections, 
fosfomycin should not be considered as a first option when other active drugs are available. 
Similar to tigecycline, fosfomycin could be useful as part of combination regimens when 
other options are limited [6,8] and to avoid emergence of resistance [169]. Fosfomycin dose 
of 16 to 24 g a day given intravenously is recommended [90]. 
8. Conclusions  
Carbapenem resistance represents one of the biggest challenges for clinicians managing 
severe infections. The optimal treatment for CR GNB infections, however, is still not well 
established. New agents for the treatment of CRE have been recently approved or are in late-
stage development and displayed promising results. Several concerns about the use of new 
antibiotics remain, including some gaps in their activity, in particular against MBL producers, 
and limited availability of real-world studies assessing their efficacy in clinical practice. In 
the current scenario, clinicians and antimicrobial stewards have to rely on available 
antimicrobials and try to optimize the use of novel available compounds to avoid the selection 
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of further resistances. Careful use of currently available options along with adequate infection 
prevention procedures and optimized AMS programs remain key points to manage severe 
infections caused by MDR GNB.  
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Figure Legends 
Figure 1. Recommendations for the use of old and new antibiotics against multidrug resistant 
Gram-negative bacilli. 
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Table 1. Current developmental status and indications of new antibiotics active against 
multidrug resistant Gram-negative bacilli 
 
Category and drug Current Status Indication 
“Old” -lactam antibiotics combined with new -lactamase inhibitors 
 
 
Ceftazidime-avibactam 
   
  
FDA-approved 
cUTI, including pyelonephritis; 
cIAI (in combination with 
metronidazole); 
HAP / VAP due to susceptible aerobic 
Gram negative bacilli 
Imipenem-relebactam  FDA - IDIQ “fast-track”  
Meropenem-vaborbactam FDA-approved cUTI, including pyelonephritis 
Aztreonam-avibactam                                                         Phase 3 trial  
New -lactam antibiotics 
 
Ceftolozane-tazobactam 
   
FDA-approved 
cUTI, including pyelonephritis; 
cIAI (in combination with 
metronidazole) 
Cefiderocol (S-649266)  Phase 3 trial  
Non--lactam antibiotics 
Plazomicin   FDA-approved cUTI, including pyelonephritis  
Eravacycline   FDA-approved cIAI 
FDA = Food and Drug Administration; IDIQ = indefinite delivery/indefinite quantity; cUTI = complicated urinary tract 
infections; cIAI = complicated intra-abdominal Infections. 
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Table 2. Randomised clinical trials in patients with carbapenem-resistant organisms  
 
Trial number  Drug Comparator Type of infection Study design; patient n; 
expected completion date 
NCT02168946 Meropenem-
vaborbactam 
 
Best available therapy BSI or HAP or cUTI/acute 
pyelonephritis due to CRE 
Open-label; n=77; 
completed in July 2017 
NCT02452047 Imipenem- 
relebactam 
Imipenem plus colistin HAP; cIAI; cUTI due to CR-
GNB 
Double-blind; n=50; 
completed in September 
2017 
 
NCT02714595 
 
Cefiderocol 
(S-649266) 
 
Best available therapy 
 
HAP; cUTI; BSI; sepsis due to 
CRE, CR-GNB 
 
Open-label; n=150; April 
2019 
 
NCT01597973 Colistin plus 
meropenem 
Colistin monotherapy BSI or pneumonia due to CRE, 
XDR-Pseudomonas or XDR-
Acinetobacter 
Double-blind; n=444; 
September 2021 
NCT01732250 Colistin plus 
meropenem 
Colistin monotherapy BSI, pneumonia or UTI due to 
CR, colistin susceptible 
organisms 
Open-label; n=360; 
completed in February 
2017 
NCT03159078 Polymyxin B Polymyxin B plus 
Carbapenem BSI, HAP, VAP, cUTI due to 
CR polymixin susceptible only 
organisms 
Double-blind; n=40; 
December 2018 
 
BSI=bloodstream infections, HAP=hospital-acquired pneumonia, V P= ventilator-associated pneumonia, CRE=carbapenem-resistant 
Enterobacteriaceae, cUTI=complicated urinary tract infections, cIAI=complicated intra-abdominal infections, GNB= Gram-negative 
bacteria 
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Table 3. Currently available carbapenem-sparing regimens for empiric and confirmed 
infections due to multidrug resistant Enterobacteriaceae  
 
Type of infection Carbapenem-based regimen 
 
Carbapenem-sparing regimen 
Empiric treatment for suspected 
ESBL  
Meropenem/
1
Doripenem [10, 99-102, 
108] 
2
Piperacillin-tazobactam ± 
aminoglycosides [9, 99-102, 
106,109] 
Confirmed ESBL (piperacillin-
tazobactam susceptible)  
Meropenem/
1
Doripenem [10, 99-102, 
108] 
2
Piperacillin-tazobactam [9, 99-
102]; 
3
consider tigecycline  
Confirmed ESBL (piperacillin-
tazobactam resistant) 
Meropenem/
1
Doripenem [10, 99-102] Ceftazidime-avibactam or 
Ceftolozane-tazobactam 
[19,33,38,43,102-104]; 
2 
consider 
tigecycline 
Suspected or confirmed CRE Meropenem-vaborbactam [46]; 
Meropenem/
1
Doripenem (combined 
with an aminoglycosides, colistin         
or tigecycline) [5,6,8, 83,93,94] 
Ceftazidime-avibactam ± 
adjunctive drug [19,33,42,113] 
1Doripenem is not indicated for the treatment of VAP due to lower clinical cure rates and increased mortality compared to 
imipenem-cilastatin (drug label revisions including FDA warning performed in 2014) [170,171] 
2Carbapenem preferred in high inoculum infections and patients with septic shock [104,105]; a recent RCT did not support 
noninferiority of piperacillin-tazobactam versus meropenem [108] 
3According to susceptibility data and type of infection; limited data available 
ESBL=extended spectrum -lactamases; CRE=carbapenem-resistant Enterobacteriaceae 
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Highlights 
 
 Carbapenem resistance represents one of the biggest challenges for clinicians managing 
severe Gram-negative infections 
 Novel antimicrobials active on carbapenem-resistant Enterobacteriaceae, ceftazidime-
avibactam and meropenem-vaborbactam, have been recently approved for clinical use 
 Ceftazidime-avibactam and meropenem-vaborbactam showed improved clinical outcomes in 
the treatment of infections caused by KPC-producing Enterobacteriaceae compared with old 
antibiotics 
 Optimization in the use of old antibiotics (carbapenems, aminoglycosides, fosfomycin, 
colistin) and careful use of novel compounds currently represent key elements to otimize 
antimicrobial stewardship programs 
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